FY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. Decreased by Analyst (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at Wedbush lowered their FY2027 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals in a research note issued to investors on Tuesday, May 7th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of $0.61 for the year, down from their previous estimate of $0.78. Wedbush currently has a "Outperform" rating and a $33.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' FY2028 earnings at $2.42 EPS.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC reissued a "buy" rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating for the company in a research note on Tuesday, February 27th. HC Wainwright lowered their price objective on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Tuesday. Oppenheimer restated a "market perform" rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Finally, Piper Sandler reiterated an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $37.67.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN traded down $0.03 on Thursday, reaching $16.38. 677,514 shares of the company traded hands, compared to its average volume of 885,664. The stock has a market capitalization of $1.43 billion, a PE ratio of -6.89 and a beta of -1.44. The company's 50 day moving average is $15.46 and its 200-day moving average is $14.19. Day One Biopharmaceuticals has a fifty-two week low of $9.67 and a fifty-two week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Partners LLC acquired a new position in Day One Biopharmaceuticals in the fourth quarter worth about $29,000. China Universal Asset Management Co. Ltd. grew its position in shares of Day One Biopharmaceuticals by 130.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company's stock worth $27,000 after buying an additional 1,262 shares during the period. Quintet Private Bank Europe S.A. boosted its position in shares of Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock worth $48,000 after purchasing an additional 1,000 shares during the last quarter. Amalgamated Bank boosted its stake in Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company's stock worth $106,000 after acquiring an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company's stock worth $147,000 after acquiring an additional 2,554 shares in the last quarter. 87.95% of the stock is owned by institutional investors.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 2,258 shares of the firm's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the sale, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Charles N. York II sold 8,078 shares of the business's stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $144,192.30. Following the sale, the chief financial officer now owns 217,293 shares in the company, valued at $3,878,680.05. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 195,247 shares of company stock worth $3,376,817. Company insiders own 8.40% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.